Stock Events

Stock Events

Ionis Pharmaceuticals 

$58.09
88
-$0.04-0.07% 20:00 Today
-$7.30-12.56%21:37After hours

Statistics

Day High
58.96
Day Low
57.79
52W High
86.74
52W Low
50.01
Volume
2,306,673
Avg. Volume
3,000,826
Mkt Cap
9.65B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.22
-0.58
0.06
0.7
Expected EPS
-1.2159
Actual EPS
N/A

Financials

-40.41%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
943.71MRevenue
-381.39MNet Income

Analyst Ratings

96.25Average Price Target
The highest estimate is 129.00.
From 17 ratings within the last 6 months. This is not an investment recommendation.
Buy
82%
Hold
18%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IONS. It's not an investment recommendation.
Apple
19
AAPL
NVIDIA
19
NVDA
Alphabet
18
GOOGL
Amazon
17
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, directly competing with Ionis in the genetic disorder treatment space.
Biogen
BIIB
Mkt Cap32.28B
Biogen collaborates with Ionis on Spinraza but also competes in developing treatments for neurological disorders.
Moderna
MRNA
Mkt Cap55.09B
Moderna's focus on mRNA technology for drug development places it in competition with Ionis's antisense technology.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics competes in the development of genetic treatments, particularly for Duchenne muscular dystrophy, overlapping with Ionis's target areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals competes in the cystic fibrosis market, where Ionis also has interests through its drug development efforts.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap11.99B
Arrowhead Pharmaceuticals focuses on RNAi therapeutics for treating chronic diseases, competing with Ionis in the RNA space.
PTC Therapeutics
PTCT
Mkt Cap5.85B
PTC Therapeutics focuses on the discovery and commercialization of novel medicines, including for genetic disorders, competing with Ionis.

About

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
Show more...
CEO
Brett Monia
Employees
1402
Country
United States
ISIN
US4622221004
WKN
000A2ACMZ

Listings

MI
IT
1IONS.MI
XETRA
DE
ISI.XETRA
STU
DE
ISI.STU
MU
DE
ISI.MU

0 Comments

Share your thoughts

FAQ

What is Ionis Pharmaceuticals stock price today?▼
The current price of IONS is $58.09 USD — it has decreased by -0.07% in the past 24 hours. Watch Ionis Pharmaceuticals stock price performance more closely on the chart.
What is Ionis Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Ionis Pharmaceuticals stocks are traded under the ticker IONS.
Is Ionis Pharmaceuticals stock price growing?▼
IONS stock has fallen by -4.85% compared to the previous week, the month change is a +5.48% rise, over the last year Ionis Pharmaceuticals has showed a -2.12% decrease.
What is Ionis Pharmaceuticals market cap?▼
Today Ionis Pharmaceuticals has the market capitalization of 9.65B
When is the next Ionis Pharmaceuticals earnings date?▼
Ionis Pharmaceuticals is going to release the next earnings report on November 04, 2026.
What were Ionis Pharmaceuticals earnings last quarter?▼
IONS earnings for the last quarter are -0.69 USD per share, whereas the estimation was -1.09 USD resulting in a +36.63% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ionis Pharmaceuticals revenue for the last year?▼
Ionis Pharmaceuticals revenue for the last year amounts to 943.71M USD.
What is Ionis Pharmaceuticals net income for the last year?▼
IONS net income for the last year is -381.39M USD.
How many employees does Ionis Pharmaceuticals have?▼
As of September 04, 2026, the company has 1,402 employees.
In which sector is Ionis Pharmaceuticals located?▼
Ionis Pharmaceuticals operates in the Health & Wellness sector.
When did Ionis Pharmaceuticals complete a stock split?▼
Ionis Pharmaceuticals has not had any recent stock splits.
Where is Ionis Pharmaceuticals headquartered?▼
Ionis Pharmaceuticals is headquartered in CARLSBAD, United States.